On June 25, 2026, Firefly Neuroscience, Inc. and an accredited investor mutually agreed to terminate a securities purchase agreement dated May 6, 2026. The agreement would have seen the company issue up to 666,667 units at $1.50 per unit for aggregate gross proceeds of up to $1,000,000. The company operates in the healthcare technology industry, developing neuroscience-based diagnostic and therapeutic solutions.

On June 18, 2026, Gil Issachar transitioned from Chief Technology Officer to Head of AI and Neuroscience under a new employment agreement with Deel Innovation Ltd. Consequently, the board of directors determined that Issachar is no longer classified as a Section 16 or executive officer of the company. Firefly Neuroscience operates in the healthcare technology industry, providing AI-driven neuroscience solutions.